Close
Almac
Achema middle east

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...
- Advertisement -

Thermo Fisher Scientific, the world leader in serving science, announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time. Providing insights on chromosomal variants for a wide range of prenatal, postnatal and oncology research applications, the Applied Biosystems™ CytoScan™ HD Accel array analyzes the whole human genome and provides improved coverage in more than 5,000 critical genome regions.

With growing demand for laboratory services and an ongoing shortage of trained lab professionals, labs are under pressure to improve efficiency to keep up with increasing volumes.i CytoScan HD Accel array can help labs increase assay productivity by up to 100% with their existing installed equipment base. The new array also minimizes sample handling and preparation time, and requires up to 50% less input sample – as little as 100 ng input DNA – than other commercially available chromosomal microarrays.

“Thermo Fisher Scientific is committed to innovation to meet the needs of our customers,” said Kevin Lowitz, vice president and general manager, microarray genetic solutions, Thermo Fisher Scientific. “By speeding up cytogenetic research time to results, the CytoScan HD Accel array can save labs weeks, or even months, over the course of a year. With its scalability and ability to provide reliable, reproducible answers faster, microarray technology will only grow in utility as a cost-effective platform of choice for cytogenetic research.”

CytoScan HD Accel array delivers improved data quality with an expanded reference model that covers a broad range of samples including buccal swabs, saliva, amniotic fluid, chorionic villus, products of conception, and blood.

As part of its commitment to enabling customers to advance cytogenetic research, Thermo Fisher has continued to update its instrumentation and services. Thermo Fisher recently enhanced its data analysis Applied Biosystems Chromosome Analysis Suite (ChAS) software by launching CytoScan Automated Interpretation and Reporting (AIR) Solution for automated data interpretation and reporting. Thermo Fisher has also upgraded its high-performance microarray instrument for array processing, Applied Biosystems™ GeneChip™ System (GCS) 3000, with the autoloader pre-assembled inside the scanner for more efficient installation and a modernized look.

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »